Clinical trial
A Phase II Trial of Cilengitide Plus Bevacizumab in Patients With Recurrent Glioblastoma
NCT01782976 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial of Cilengitide Plus Bevacizumab in Patients With Recurrent Glioblastoma
- Lead sponsor
- M.D. Anderson Cancer Center
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- June 30, 2013
- Completion date
- Not reported
- Enrollment
- 0 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.